Risk of severe COVID-19 associated with immune-modifying drugs: data from PsoProtect and Global Rheumatology Alliance registries

Mahil S;Schaefer M;Dand N;Yiu Z;Hyrich K;Strangfeld A;Yates M;Carmona L;Gossec L;Mateus E;Lawson-Tovey S;Wiek D;Jacobsohn L;Isnardi C;Quintana R;Soriano E;Wallace Z;Bhana S;Gore-Massey M;Grainger R;Hausmann J;Liew J;Sirotich E;Mason K;Tsakok T;Meynell F;Coker B;Vincent A;Urmston D;Mcateer H;Vesty A;Kelly J;Lancelot C;Moorhead L;Mackenzie T;Rossi M;Rivera R;Mahe E;Carugno A;Magnano M;Rech G;Balogh E;Feldman S;De La Cruz C;Di Meglio P;Contreras C;Choon S;Capon F;Torres T;Naldi L;Weinman J;Brown M;Galloway J;Norton S;Lambert J;Spuls P;Van Huizen A;Jullien D;Bachelez H;Mcmahon D;Freeman E;Gisondi P;Puig L;Warren R;Langan S;Sufka P;Robinson P;Yazdany J;Griffiths C;Barker J;Machado P;Smith C

2022-01-01